Trovan

Trovan. It is the brand name for the broad-spectrum antibiotic trovafloxacin, a fluoroquinolone drug developed by the pharmaceutical company Pfizer. Introduced in the late 1990s, it was initially heralded for its potent activity against a wide range of bacterial infections, including those caused by Streptococcus pneumoniae and certain anaerobic organisms. However, its use became severely restricted and it was ultimately withdrawn from many markets following reports of severe, sometimes fatal, hepatotoxicity.

Medical uses

Trovan was indicated for the treatment of serious, life-threatening infections requiring hospitalization, such as complicated intra-abdominal infection, pelvic inflammatory disease, and severe community-acquired pneumonia. Its broad spectrum made it a potential option for nosocomial infections, including those suspected to involve multidrug-resistant pathogens like methicillin-resistant Staphylococcus aureus. The drug was also studied for use in treating meningitis and bacterial skin infection, given its ability to achieve high concentrations in various body tissues and fluids. It was available in both intravenous (as the prodrug alatrofloxacin) and oral formulations, allowing for a transition from hospital to outpatient therapy.

Adverse effects

The most significant adverse effect associated with Trovan was idiosyncratic, severe liver injury, including cases of fulminant hepatic failure requiring liver transplantation and resulting in death. Other serious risks included tendinitis and tendon rupture, a class effect of fluoroquinolone drugs, as well as potential effects on the central nervous system such as seizures and peripheral neuropathy. Common side effects mirrored those of other antibiotics and included nausea, diarrhea, dizziness, and headache. The risk of Clostridioides difficile infection, causing severe colitis, was also present, as with many broad-spectrum agents.

Pharmacology

Trovafloxacin functions by inhibiting two critical bacterial enzymes, DNA gyrase and topoisomerase IV, thereby interfering with DNA replication and transcription. It exhibits concentration-dependent bactericidal activity. Pharmacokinetically, it is well-absorbed orally with high bioavailability, and it demonstrates an extensive volume of distribution, penetrating effectively into tissues like the lung, prostate, and cerebrospinal fluid. Metabolism occurs primarily in the liver via glucuronidation, and excretion is through both the bile and urine, with a prolonged elimination half-life that allowed for once-daily dosing.

History and development

Trovan was developed by Pfizer following its acquisition of the company Goedecke. It received approval from the U.S. Food and Drug Administration in 1997 under the agency's accelerated review process. The drug was launched with a major marketing campaign, touting its once-daily convenience and efficacy against resistant pathogens. It was subsequently approved in the European Union and other global markets. Early clinical trials, such as those presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, showed promising results against a variety of serious infections, leading to its rapid adoption in hospital formularies.

Controversy and legal issues

Major controversy erupted in 1999 when the FDA issued a public health advisory following reports of over 100 cases of liver toxicity, including several deaths. This led to severe restrictions on its use, limiting it to life-threatening situations where no alternative existed. The drug was voluntarily withdrawn from the market in the European Union and its availability was drastically curtailed in the United States. A highly publicized incident involved a 1996 clinical trial in Kano, Nigeria, during a meningitis outbreak, which led to allegations of ethical misconduct against Pfizer and resulted in protracted legal battles and a settlement with the Nigerian government. These events contributed significantly to ongoing debates about pharmaceutical ethics, post-marketing surveillance, and the regulatory oversight of drug safety.

Category:Fluoroquinolone antibiotics Category:Pfiler Category:Drugs withdrawn from the market